Nurse Practitioner Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Sheena Young

Nurse Practitioner Hayden, ID Nurse Practitioner

NPI 1154965986 CMS profile 11071685

1986 W Hayden Ave, Hayden, ID 83835

Open in the dashboard

General payments

$2,049

111 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Sheena Young of Hayden, ID is reported in the CMS Open Payments database as having received $2,049 across 111 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $668 37
2022 General $748 42
2021 General $633 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sheena Young
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Sheena Young were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Sheena Young Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $633 $135 $40–$426 $132
2022 $748 $152 $48–$470 $149
2023 $668 $166 $54–$529 $160
2024 $0 $173 $55–$556 $164
2025 $0 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. AstraZeneca Pharmaceuticals LP $514 30 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $319 18 payments
  3. Novo Nordisk Inc $183 9 payments
  4. Otsuka America Pharmaceutical, Inc. $182 9 payments
  5. Akebia Therapeutics Inc $163 8 payments
  6. Amgen Inc. $130 8 payments
  7. Calliditas Therapeutics US Inc. $127 7 payments
  8. Relypsa, Inc. $117 5 payments
  9. Aurinia Pharma U.S., Inc. $109 6 payments
  10. GlaxoSmithKline, LLC. $81 5 payments
  11. Other $124 6 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $2,043 110 payments
  2. Education $7 1 payment
Products named General payments · program years 2021–2023
  1. Kerendia $319 18 payments
  2. LOKELMA $281 16 payments
  3. FARXIGA $211 12 payments
  4. JYNARQUE $182 9 payments
  5. Auryxia $163 8 payments
  6. RYBELSUS $155 7 payments
  7. TARPEYO $127 7 payments
  8. Veltassa $117 5 payments
  9. LUPKYNIS $109 6 payments
  10. Parsabiv $92 6 payments
  11. Other $349 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

265

Median for Nurse Practitioner: 389

Drug cost

$23,022

Median for Nurse Practitioner: $21,885

Branded share of claims

10.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 17 $16,368
Ramelteon Generic 15 $2,675
Desmopressin Acetate Desmopressin (Nonrefrigerated) Brand 11 $873
Eszopiclone Generic 13 $786
Gabapentin Generic 62 $689
Torsemide Generic 20 $441
Potassium Chloride Generic 15 $359
Clonazepam Generic 29 $214
Irbesartan Generic 12 $198
Carvedilol Generic 16 $181

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$29,142

Medicare's payments for the services billed

Medicare patients

515

Average age 72

Services billed

678

239 women, 276 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 33%
Ischemic heart disease 27%
Depression 27%
Atrial fibrillation 26%
Chronic kidney disease 24%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

111 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record